195 related articles for article (PubMed ID: 23065693)
1. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
Wang WY; Twu CW; Chen HH; Jiang RS; Wu CT; Liang KL; Shih YT; Chen CC; Lin PJ; Liu YC; Lin JC
Cancer; 2013 Mar; 119(5):963-70. PubMed ID: 23065693
[TBL] [Abstract][Full Text] [Related]
2. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
[TBL] [Abstract][Full Text] [Related]
3. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
7. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
8. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
[TBL] [Abstract][Full Text] [Related]
9. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.
Hassen E; Farhat K; Gabbouj S; Bouaouina N; Abdelaziz H; Chouchane L
Biomarkers; 2011 May; 16(3):274-80. PubMed ID: 21506698
[TBL] [Abstract][Full Text] [Related]
11. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
12. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
[TBL] [Abstract][Full Text] [Related]
13. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
14. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
[TBL] [Abstract][Full Text] [Related]
16. Plasma Epstein-Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area.
Shen T; Tang LQ; Gu WG; Luo DH; Chen QY; Li PJ; Mai DM; Mai HQ; Mo HY
Medicine (Baltimore); 2015 Dec; 94(50):e1945. PubMed ID: 26683909
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
Tan EL; Looi LM; Sam CK
Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer.
Hui EP; Ma BBY; Lam WKJ; Chan KCA; Mo F; Ai QH; King AD; Wong CH; Wong KCW; Lam DCM; Tong M; Poon DMC; Li L; Lau TKH; Wong KH; Lo YMD; Chan ATC
Clin Cancer Res; 2021 May; 27(10):2827-2836. PubMed ID: 33692028
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
20. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
Le QT; Jones CD; Yau TK; Shirazi HA; Wong PH; Thomas EN; Patterson BK; Lee AW; Zehnder JL
Clin Cancer Res; 2005 Aug; 11(16):5700-7. PubMed ID: 16115906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
